In patients with Becker muscular dystrophy (BMD), creatine/creatinineratio(Cr/Crn) and myostatin can reasonably predict patients’ functional performance after adjusting for age.
Why this matters?
Clinical trials in BMD have been met with challenges such as very low recruitment, difficulty with demonstrating treatment efficacy for example. Objective biomarkers are still lacking.
Cr/Crn and myostatin can potentially serve as monitoring biomarkers in patients with BMD.